Tag Archives: GLP-1

Blood glucose may improve dramatically after metabolic or bariatric surgery. Yet, for some patients, a very different glucose problem develops months or years later. Post-bariatric hypoglycemia can cause sudden drops in blood glucose after meals, with symptoms ranging from sweating and tremor to confusion, seizures, or loss of consciousness. Because …

For decades, glucagon has been viewed as insulin’s opposite. While insulin lowers blood glucose, glucagon raises it by signaling the liver to release stored sugar into the bloodstream. Because of this, glucagon has traditionally been considered a hormone to suppress in people living with type 2 diabetes. However, modern research …

For decades, metformin has been the backbone of type 2 diabetes therapy. As we move through 2026, the future of metformin in type 2 diabetes treatment is under fresh scrutiny. Should it still be the first-line agent, or have newer drug classes like GLP‑1 receptor agonists and SGLT2 inhibitors earned …

Nonalcoholic steatohepatitis (NASH) and metabolic dysfunction–associated steatotic liver disease (MASLD) are rapidly becoming leading causes of chronic liver disease worldwide. Traditionally, clinicians have associated MASLD with obesity, insulin resistance, and type 2 diabetes, often using body mass index (BMI) and A1C as screening triggers. However, an important shift is occurring …

The class of medications known as GLP-1 receptor agonists — commonly prescribed for type 2 diabetes and increasingly used for weight loss — may offer more than just metabolic benefits. Growing evidence indicates that GLP-1 drugs could play a role in protecting the brain. Could this mean a dual benefit …